2390 Stock Overview
Guizhou Xinbang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Guizhou Xinbang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥3.80 |
52 Week High | CN¥5.25 |
52 Week Low | CN¥3.18 |
Beta | 0.50 |
1 Month Change | -3.55% |
3 Month Change | -13.83% |
1 Year Change | -23.69% |
3 Year Change | -56.27% |
5 Year Change | -36.77% |
Change since IPO | -27.78% |
Recent News & Updates
Recent updates
Shareholder Returns
2390 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -5.5% | -1.6% | -0.03% |
1Y | -23.7% | -8.6% | -14.2% |
Return vs Industry: 002390 underperformed the CN Pharmaceuticals industry which returned -8.6% over the past year.
Return vs Market: 002390 underperformed the CN Market which returned -14.2% over the past year.
Price Volatility
2390 volatility | |
---|---|
2390 Average Weekly Movement | 5.0% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 8.1% |
10% most volatile stocks in CN Market | 11.3% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002390 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002390's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 5,408 | Lingzhong Kong | https://www.xinbang.com |
Guizhou Xinbang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally. The company offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medicine, gynecological treatment, and anti-infective drugs. It also operates in medical services; and pharmaceutical circulation business.
Guizhou Xinbang Pharmaceutical Co., Ltd. Fundamentals Summary
2390 fundamental statistics | |
---|---|
Market cap | CN¥7.33b |
Earnings (TTM) | CN¥230.02m |
Revenue (TTM) | CN¥6.49b |
31.8x
P/E Ratio1.1x
P/S RatioIs 2390 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2390 income statement (TTM) | |
---|---|
Revenue | CN¥6.49b |
Cost of Revenue | CN¥5.25b |
Gross Profit | CN¥1.23b |
Other Expenses | CN¥1.00b |
Earnings | CN¥230.02m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 16, 2024
Earnings per share (EPS) | 0.12 |
Gross Margin | 19.00% |
Net Profit Margin | 3.55% |
Debt/Equity Ratio | 15.8% |
How did 2390 perform over the long term?
See historical performance and comparison